Sanofi Pasteur Plans Vaccine Research and Production Facilities

Published 6-24-2020

Sanofi Pasteur is planning to create the Evolutive Vaccine Facility (EVF) in Neuville sur Saône, France. Representing an investment of €490 million over a five-year period, the structure will house a central unit containing several fully digital production modules, enabling the manufacture of four vaccines simultaneously. This modularity will make it possible to prioritize the delivery of a specific vaccine to address crucial public health issues. The company will also invest €120 million to construct a new R&D center in Marcy-l'Etoile. The state-of-the-art digital facility will feature highly specialized laboratories to support the development of future vaccines for the treatment of emerging infectious diseases.